Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Hochhaus, Andreas  [Clear All Filters]
2013
Spies-Weisshart B, Schilling K, Böhmer F, Hochhaus A, Sayer HG, Scholl S. Lack of association of platelet-derived growth factor (PDGF) receptor autoantibodies and severity of chronic graft-versus-host disease (GvHD). J Cancer Res Clin Oncol. 2013.
2014
Schnetzke U, Fix P, Spies-Weisshart B, Schrenk K, Glaser A, Fricke H-J, La Rosée P, Hochhaus A, Scholl S. Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML). J Cancer Res Clin Oncol. 2014.
2016
Karrasch M, Schmidt V, Hammer A, Hochhaus A, La Rosée P, Petersen I, Sauerbrei A, Baier M, Sayer HG, Hermann B. Chronic persistent parvovirus B19 bone marrow infection resulting in transfusion-dependent pure red cell aplasia in multiple myeloma after allogeneic haematopoietic stem cell transplantation and severe graft versus host disease. Hematology. 2016:1-6.
Winkelmann N, Desole M, Hilgendorf I, Ernst T, Sayer HG, Kunert C, Mügge L-O, Hochhaus A, Scholl S. Comparison of two dose levels of cyclophosphamide for successful stem cell mobilization in myeloma patients. J Cancer Res Clin Oncol. 2016.
2020
Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020.
2021
Mühleck R, Scholl S, Hilgendorf I, Schrenk K, Hammersen J, Frietsch JJ, Fleischmann M, Sayer HG, Glaser A, Hochhaus A, et al. Outcome of patients with relapsed or refractory acute myeloid leukemia treated with Mito-FLAG salvage chemotherapy. J Cancer Res Clin Oncol. 2021.
Schnoeder TM, Schwarzer A, Jayavelu AKumar, Hsu C-J, Kirkpatrick J, Döhner K, Perner F, Eifert T, Huber N, Arreba-Tutusaus P, et al. PLCG1 is required for AML1-ETO leukemia stem cell self-renewal. Blood. 2021.
2022
Fleischmann M, Scholl S, Frietsch JJ, Hilgendorf I, Schrenk K, Hammersen J, Prims F, Thiede C, Hochhaus A, Schnetzke U. Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia. J Cancer Res Clin Oncol. 2022.
Koschmieder S, Isfort S, Wolf D, Heidel FH, Hochhaus A, Schafhausen P, Griesshammer M, Wolleschak D, Platzbecker U, Döhner K, et al. Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. Ann Hematol. 2022.
Brioli A, Nägler TMaria, Yomade O, Rüthrich MMadeleine, Scholl S, Frietsch JJ, Hilgendorf I, Ernst T, Sayer HGottfried, Hochhaus A, et al. Sex-disaggregated analysis of biology, treatment tolerability and outcome of Multiple Myeloma in a German cohort. Oncol Res Treat. 2022.
2023
Eifert T, Hsu C-J, Becker AL, Graessle S, Horne A, Bemmann F, Zhang Q, Heuser M, Vasioukhin V, Scholl S, et al. Cell fate determinant Llgl1 is required for propagation of acute myeloid leukemia. Leukemia. 2023.
Niederwieser D, Lang T, Krahl R, Heinicke T, Maschmeyer G, Al-Ali HKathrin, Schwind S, Jentzsch M, Cross M, Kahl C, et al. Different treatment strategies versus a common standard arm (CSA) in patients with newly diagnosed AML over the age of 60 years: a randomized German inter-group study. Ann Hematol. 2023.
Tubío-Santamaría N, Jayavelu AKumar, Schnoeder TM, Eifert T, Hsu C-J, Perner F, Zhang Q, Wenge DV, Hansen FM, Kirkpatrick JM, et al. Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia. Mol Cancer. 2023;22(1):196.
2024
Mahon F-X, Pfirrmann M, Dulucq S, Hochhaus A, Panayiotidis P, Almeida A, Mayer J, Hjorth-Hansen H, Janssen JJWM, Mustjoki S, et al. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission. J Clin Oncol. 2024:JCO2301647.